Daiichi Sankyo
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Daiichi Sankyo sits in the top decile of US sponsors by registered trial count (#139 of 15,742 sponsors by registered trial count).
Daiichi Sankyo: 236 sponsored US clinical trials, 29 recruiting.
Daiichi Sankyo sponsors 236 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 167 completed. 71 of these trials are in Phase 3-4 (later-stage) and 153 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 7 trials.
Top-decile sponsor footprint
Daiichi Sankyo ranks in the top decile of sponsors by registered trial count (#139 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 189 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
236 total, page 2 of 5
A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate
NCT06772246
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer
NCT06686602
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
NCT06557967
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
NCT06040593
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
NCT05638802
A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer
NCT05769764
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
NCT05583669
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
NCT05569252
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
NCT05388903
A Study of DS-9606a in Patients With Advanced Solid Tumors
NCT05394675
A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
NCT05203692
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
NCT05025722
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
NCT04484142
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT04644237
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
NCT04744831
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
NCT04526704
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
NCT04473664
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
NCT04479436
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
NCT04276415
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
NCT04223635
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
NCT04014075
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
NCT04276662
Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
NCT03901313
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
NCT03552029
Food Effects on Milademetan Pharmacokinetics in Healthy Participants
NCT03647202
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
NCT03523572
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03523585
Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants
NCT03614455
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
NCT03505710
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
NCT03395639
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
NCT03291288
Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
NCT04033094
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
NCT03248492
DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
NCT03305471
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
NCT03110354
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
NCT02798471
Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
NCT02943785
Effect of Probenecid on Pexidartinib Pharmacokinetics
NCT03138759
Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
NCT02991196
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
NCT02948088
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
NCT02668653
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
NCT02923115
A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects
NCT02790671
A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects
NCT02790684
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
NCT02647320
The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers
NCT04019652
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
NCT02586233
Cancer Venous Thromboembolism (VTE)
NCT02073682
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
NCT02452424
Study of DS-7080a for the Treatment of Macular Degeneration
NCT02530918
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 90 |
| Phase 2 | 63 |
| Phase 3 | 50 |
| Phase 4 | 21 |
What is open in the Daiichi Sankyo pipeline
29 recruiting of 236 indexed (12% open); 167 completed (71%).
Phase mix: 71 late (III/IV) vs 153 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Daiichi Sankyo: open-pipeline peers nationwide
Peers matched on 236 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Daiichi Sankyo sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 236 trials (± recruiting share)
- Loma Linda University · 237 trials · 15% recruiting
- Henry Ford Health System · 234 trials · 18% recruiting
- Incyte Corporation · 239 trials · 15% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 12% open enrollment (± trial volume)
- University of Iowa · 12% recruiting · 228 trials
- Augusta University · 12% recruiting · 106 trials
- National Institute of Mental Health (NIMH) · 12% recruiting · 343 trials
- National Heart, Lung, and Blood Institute (NHLBI) · 12% recruiting · 501 trials
Related
What to do with this Daiichi Sankyo page
236 registered trials is a research-attention snapshot, not an endorsement of Daiichi Sankyo or any single study.
- 29 of Daiichi Sankyo's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition Daiichi Sankyo studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Daiichi Sankyo pipeline card: 236 registered trials from official public datasets.Report a data error.